In a milestone for the hematologic oncology landscape, the first patient has been dosed in a phase 1/2 clinical trial (NCT07220616) evaluating DS3790, a potential first-in-class antibody-drug ...

Mir195 enables Ebf1-deficient hematopoietic progenitor cells to mature into B cells, suggesting some miRNA can substitute for transcription factors in differentiation.

In this interview, industry experts Mathieu Bennet and Dustin Whitson explore how automation and single-cell technologies are transforming high-throughput B-cell cloning for antibody discovery. Can ...

Sonrotoclax is a next-generation and potentially best-in-class investigational B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Studies in the lab and ...

B cell development in swine presents a unique model within mammalian immunology. In contrast to traditional murine and human systems, swine exhibit notable differences in the temporal order of heavy ...

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...

The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or ...

Findings published today in Nature Cancer from Charles Mullighan, MBBS (Hons), MSc, MD, deputy director of the St. Jude Comprehensive Cancer Center, Department of Pathology, and collaborators show ...

New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B ...

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...

In the 13 th century, unusual skin lesions resembling wolf bites led to the term "lupus," meaning "wolf" in Latin. These symptoms also took the form of a butterfly across the face and to other parts ...